180 related articles for article (PubMed ID: 17941878)
1. Identification of negative predictors of pain-free response to triptans: analysis of the eletriptan database.
Diener HC; Dodick DW; Goadsby PJ; Lipton RB; Almas M; Parsons B
Cephalalgia; 2008 Jan; 28(1):35-40. PubMed ID: 17941878
[TBL] [Abstract][Full Text] [Related]
2. Predictors of migraine headache recurrence: a pooled analysis from the eletriptan database.
Dodick DW; Lipton RB; Goadsby PJ; Tfelt-Hansen P; Ferrari MD; Diener HC; Almas M; Albert KS; Parsons B
Headache; 2008 Feb; 48(2):184-93. PubMed ID: 18234045
[TBL] [Abstract][Full Text] [Related]
3. Eletriptan for the acute treatment of migraine in adolescents: results of a double-blind, placebo-controlled trial.
Winner P; Linder SL; Lipton RB; Almas M; Parsons B; Pitman V
Headache; 2007 Apr; 47(4):511-8. PubMed ID: 17445100
[TBL] [Abstract][Full Text] [Related]
4. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life.
Mathew NT; Landy S; Stark S; Tietjen GE; Derosier FJ; White J; Lener SE; Bukenya D
Headache; 2009 Jul; 49(7):971-82. PubMed ID: 19486178
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of eletriptan in triptan-naïve patients: results of a combined analysis.
Martin VT; Valade D; Almas M; Hettiarachchi J; Sikes C; Albert KS; Parsons B
Headache; 2007 Feb; 47(2):181-8. PubMed ID: 17300357
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of almotriptan 12.5 mg in achieving migraine-related composite endpoints: a double-blind, randomized, placebo-controlled study in patients controlled study in patients with previous poor response to sumatriptan 50 mg.
Diener HC
Curr Med Res Opin; 2005 Oct; 21(10):1603-10. PubMed ID: 16238900
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic benefit of eletriptan compared to sumatriptan for the acute relief of migraine pain--results of a model-based meta-analysis that accounts for encapsulation.
Mandema JW; Cox E; Alderman J
Cephalalgia; 2005 Sep; 25(9):715-25. PubMed ID: 16109054
[TBL] [Abstract][Full Text] [Related]
8. Eletriptan in migraine patients reporting unsatisfactory response to rizatriptan.
Goldstein J; Tiseo PT; Albert KS; Li C; Sikes CR
Headache; 2006; 46(7):1142-50. PubMed ID: 16866718
[TBL] [Abstract][Full Text] [Related]
9. Early intervention with almotriptan: results of the AEGIS trial (AXERT Early Migraine Intervention Study).
Mathew NT; Finlayson G; Smith TR; Cady RK; Adelman J; Mao L; Wright P; Greenberg SJ;
Headache; 2007 Feb; 47(2):189-98. PubMed ID: 17300358
[TBL] [Abstract][Full Text] [Related]
10. Effect of pain intensity and time to administration on responsiveness to almotriptan: results from AXERT 12.5 mg Time Versus Intensity Migraine Study (AIMS).
Freitag FG; Finlayson G; Rapoport AM; Elkind AH; Diamond ML; Unger JR; Fisher AC; Armstrong RB; Hulihan JF; Greenberg SJ;
Headache; 2007 Apr; 47(4):519-30. PubMed ID: 17445101
[TBL] [Abstract][Full Text] [Related]
11. Eletriptan in the early treatment of acute migraine: influence of pain intensity and time of dosing.
Brandes JL; Kudrow D; Cady R; Tiseo PJ; Sun W; Sikes CR
Cephalalgia; 2005 Sep; 25(9):735-42. PubMed ID: 16109056
[TBL] [Abstract][Full Text] [Related]
12. [Economic evaluation of acute migraine attack treatment with triptans in Spain].
Gracia-Naya M; Rejas Gutiérrez J; Latorre Jiménez A; González Garcia P
Neurologia; 2005 Apr; 20(3):121-32. PubMed ID: 15815947
[TBL] [Abstract][Full Text] [Related]
13. Treatment-emergent CNS symptoms following triptan therapy are part of the attack.
Goadsby PJ; Dodick DW; Almas M; Diener HC; Tfelt-Hansen P; Lipton RB; Parsons B
Cephalalgia; 2007 Mar; 27(3):254-62. PubMed ID: 17381558
[TBL] [Abstract][Full Text] [Related]
14. Meta-analysis of the efficacy and safety of zolmitriptan in the acute treatment of migraine.
Chen LC; Ashcroft DM
Headache; 2008 Feb; 48(2):236-47. PubMed ID: 18179569
[TBL] [Abstract][Full Text] [Related]
15. Outcome for headache and pain-free nonresponders to treatment of the first attack: a pooled post-hoc analysis of four randomized trials of eletriptan 40 mg.
Landy SH; Tepper SJ; Schweizer E; Almas M; Ramos E
Cephalalgia; 2014 Apr; 34(5):376-81. PubMed ID: 24265285
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of eletriptan in migraine-related functional impairment: functional and work productivity outcomes.
Silberstein SD; Cady RK; Sheftell FD; Almas M; Parsons B; Albert KS
Headache; 2007 May; 47(5):673-82. PubMed ID: 17501848
[TBL] [Abstract][Full Text] [Related]
17. Comparing the efficacy of eletriptan for migraine in women during menstrual and non-menstrual time periods: a pooled analysis of randomized controlled trials.
Bhambri R; Martin VT; Abdulsattar Y; Silberstein S; Almas M; Chatterjee A; Ramos E
Headache; 2014 Feb; 54(2):343-54. PubMed ID: 24256184
[TBL] [Abstract][Full Text] [Related]
18. Post Hoc Subanalysis of Two Randomized, Controlled Phase 3 Trials Evaluating Diclofenac Potassium for Oral Solution: Impact of Migraine-Associated Nausea and Prior Triptan Use on Efficacy.
Lipton RB; Schmidt P; Diener HC
Headache; 2017 May; 57(5):756-765. PubMed ID: 28386945
[TBL] [Abstract][Full Text] [Related]
19. The 'Act when Mild' (AwM) study: a step forward in our understanding of early treatment in acute migraine.
Goadsby PJ
Cephalalgia; 2008 Sep; 28 Suppl 2():36-41. PubMed ID: 18715331
[TBL] [Abstract][Full Text] [Related]
20. [Spanish contribution to the clinical development of eletriptan: an analysis of controlled studies].
Pascual J; Leira R; Lainez JM; Liaño H; Díez-Tejedor E; Navarro A; Jiménez D; Ezpeleta D; Mateos V; Madrigal M; Palacios G;
Neurologia; 2004 Oct; 19(8):414-9. PubMed ID: 15470580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
